Premium
Combined c‐Myc and caveolin‐1 expression in human prostate carcinoma predicts prostate carcinoma progression
Author(s) -
Yang Guang,
Timme Terry L.,
Frolov Anna,
Wheeler Thomas M.,
Thompson Timothy C.
Publication year - 2005
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.20905
Subject(s) - medicine , prostate , immunostaining , carcinoma , tumor progression , pca3 , pathology , prostatectomy , cancer research , caveolin 1 , prostate cancer , hazard ratio , immunohistochemistry , oncology , cancer , confidence interval
BACKGROUND Over‐expression of the oncogene c‐Myc has been implicated in the development and progression of human prostate carcinoma. However, previous assessments of c‐Myc expression have not revealed its potential for predicting prostate carcinoma progression. Caveolin‐1 is associated with prostate carcinoma progression and is a downstream target gene of c‐Myc. The observation that caveolin‐1 can suppress c‐Myc‐induced apoptosis suggested the potential for cooperation between c‐Myc and caveolin‐1 in malignant progression. In this study, the authors evaluated the prognostic potential of combined c‐Myc and caveolin‐1 expression in human prostate carcinoma progression. METHODS Immunostaining with c‐Myc and caveolin‐1‐specific antibodies was performed on paraffin sections from 104 radical prostatectomy specimens from men with lymph node negative prostate carcinoma. Combined c‐Myc and caveolin‐1 immunostaining scores were related with the clinical and pathologic features and the probability of prostate‐specific antigen recurrence after surgery. RESULTS The combination of c‐Myc and caveolin‐1 immunopositivity correlated positively with Gleason score (ρ = 0.219; P = 0.0253) and positive surgical margin (ρ = 0.333; P = 0.0006). The combination of positive c‐Myc and caveolin‐1 in patients with clinically confined prostate carcinoma was a significant prognostic marker for the time to disease progression after surgery in both univariate analysis ( P = 0.0039; hazard ratio, 3.035) and multivariate analysis ( P = 0.0114; hazard ratio, 2.916). CONCLUSIONS The coexpression of c‐Myc and caveolin‐1 showed potential as a useful prognostic marker for human prostate carcinoma. The current results suggest interactions between c‐Myc and caveolin‐1 in the progression of human prostate carcinoma. Cancer 2005. © 2005 American Cancer Society.